Taken together, the present study suggested that RUNX3 regulated the differentiation of Th17 and Th22 cells in psoriasis, providing a promising therapeutic strategy for the treatment of psoriasis.
In this study, we found that the expression of RUNX3 is increased significantly while the expression of miR-138 decreased significantly in CD4(+) T cells from psoriasis patients.